AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02898012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage > grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
Study NCT00902629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery
Description: Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
Study NCT01306760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine used as the anaesthetic during ECT.
Study NCT01306760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The standard anaesthetic used for ECT.
Study NCT01776125 — intervention group
Intervention type: OTHER
Intervention: Cheek swab
Description: Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
Study NCT03506503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafting
Description: hair loss area will be treated by processed autologous Nanofat grafting
Study NCT04545957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Simulator
Description: Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
Study NCT04545957 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
Study NCT02190734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sitting in wheel chair
Description: Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
Study NCT02190734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait training on treadmill
Description: Walking on a treadmill with or without body weight support during 30 minute treatment
Study NCT02190734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait training overground
Description: Walking overground with or without body weight support during 30 minute treatment
Study NCT01967381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine (Desoxyn®)
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Study NCT01478958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SFA diet
Description: Volunteers are following a high saturated fat diet for a 4-month period
Study NCT01478958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA diet
Description: Volunteers are following a high monounsaturated fat diet for a 4-month period
Study NCT01478958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-6 PUFA diet
Description: Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
Study NCT02909153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
Study NCT03252782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst Appliance
Description: Acrylic Splint Herbst Appliance
Study NCT03252782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Jet Appliance
Description: Anterior Median Palate Implant Borne Distal Jet Appliance
Study NCT02197260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
Description: Systemic antibiotics after sub gingival mechanical debridement
Study NCT02197260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
Description: Systemic antibiotics after sub gingival mechanical debridement
Study NCT03956862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001
Description: film-coated oral tablet
Study NCT03956862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablet
Study NCT03137108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal cord stimulation
Description: Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
Study NCT02203058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed-lips breathing
Description: Expiration with pursed-lips during functional capacity tests.
Study NCT02203058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No pursed-lips breathing
Description: To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
Study NCT00469417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix® cream
Study NCT00469417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand held liquid nitrogen spray cryotherapy
Study NCT00705536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Study NCT00705536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R
Study NCT00705536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study NCT02957097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Medication used for management of neuropathic pain conditions
Study NCT02957097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
Study NCT03656913 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extremely low dose CT
Description: Patients undergoing clinically indicated CT will also receive the extremely low dose CT
Study NCT01447615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges
Description: Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
Study NCT01447615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges PLUS
Description: Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
Study NCT01447615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
Study NCT01447615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
Study NCT01824537 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine, Gardasil 9
Description: Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
Study NCT01824537 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Provided by Sanofi Pasteur.
Study NCT04207203 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: sodium zirconium cyclosilicate and healthy diet
Description: During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
Study NCT01901705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indigo naturalis ointment
Description: The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
Study NCT01901705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
Study NCT01375660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
Study NCT01375660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50K vitamin D2
Description: Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
Study NCT02694757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostom-i device
Description: The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
Study NCT02412514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV (three dose)
Description: bOPV administered at 6, 10, and 14 weeks of age.
Study NCT02412514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV (two dose)
Description: bOPV administered at 10 and 14 weeks of age.
Study NCT02412514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: IPV administered at 6 weeks of age
Study NCT00812760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa
Description: 1 tablet of 200 mg levodopa plus 50 mg benserazide
Study NCT02650921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft with Lidocaine
Description: An injectable gel of Hyaluronic Acid and Lidocaine
Study NCT04097782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenat education
Description: Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
Study NCT02530905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4045
Description: SRP-4045 solution for IV infusion.
Study NCT02530905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRP-4045 placebo-matching solution for IV infusion.
Study NCT00183521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raise-CO2 breathing regulation training
Description: Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
Study NCT00183521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-CO2 breathing regulation training
Description: According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
Study NCT00183521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
Study NCT00840125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg tablet daily
Study NCT00840125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
Study NCT02986776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Care
Description: 21 days of inpatient substance misuse treatment
Study NCT03828981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast-track recovery program
Description: Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain.
Study NCT03013634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
Study NCT03013634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equal volume normal saline substitute for dexmedetomidine
Study NCT00892892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilmenidine
Description: 1 mg Rilmenidine per day versus
Study NCT00892892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrendipine
Description: 20 mg Nitrendipine per day
Study NCT04403997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
Study NCT04403997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
Study NCT02246322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G needle
Description: All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Study NCT02246322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22G needle
Description: All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Study NCT02137135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.
Study NCT02137135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.
Study NCT02137135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
Study NCT02137135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
Study NCT02137135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.
Study NCT02137135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.
Study NCT04109521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training, certification and marketing
Description: The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
Study NCT01464112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-2641585 / VELCADE / Dexamethasone
Description: JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
Study NCT02559063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vision-based speed of processing training
Description: computerized cognitive tasks addressing vision-based speed of processing
Study NCT02559063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental leisure activities
Description: computerized cognitive tasks addressing different aspects of executive function
Study NCT01163825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor
Description: Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
Study NCT03610113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty
Description: The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
Study NCT04198844 — intervention group
Intervention type: DRUG
Intervention: warfarin
Description: warfarin user